Merck's Januvia Approved In China
This article was originally published in PharmAsia News
Executive Summary
Merck recently announced China State FDA approval of Januvia (sitagliptin), which is China's first DPP-4 inhibitor approved for the treatment of type 2 diabetes. At present, China has the world's second-largest diabetic population, trailing India. The International Diabetes Federation estimates that by 2030, the total number of people worldwide with diabetes will be more than 435 million. Currently the fourth largest cause of death worldwide, more than 3.8 million people die annually from diabetes and its complications. With both foreign and domestic companies entering the market, competition in the Chinese diabetes market will continue to heat up. (Click Here For More - Chinese Language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.